Clinical Scorecard: DRY EYE DX AND TX

At a Glance

Key Highlights

• SFAs are nonaqueous, preventing microbial growth and eliminating preservatives.
• F6H8 improves tear breakup time and lipid layer thickness.
• F4H5 enhances bioavailability of cyclosporine and shows earlier onset of action.
• Both F6H8 and F4H5 are FDA approved and commercially available.
• Clinical trials demonstrate significant improvements in dry eye symptoms.

Guideline-Based Recommendations

Diagnosis

• Assess symptoms and signs of dry eye disease using standardized questionnaires and tests.

Management

• Consider SFA-based therapies for patients unresponsive to standard treatments.

Monitoring & Follow-up

• Regularly evaluate tear breakup time and patient-reported symptoms.

Risks

• Monitor for potential ocular discomfort or irritation from new therapies.

Patient & Prescribing Data

Patients with moderate to severe dry eye disease, particularly those with meibomian gland dysfunction.

SFAs provide dual action by reducing evaporation and addressing inflammation.

Clinical Best Practices

• Utilize nonaqueous formulations to minimize irritation.
• Incorporate patient education on the benefits of new SFA therapies.
• Monitor treatment efficacy and adjust management plans as necessary.

References

• Tsagogiorgas C, Otto M. Semifluorinated Alkanes as New Drug Carriers-An Overview of Potential Medical and Clinical Applications.
• Delicado-Miralles M, et al. Deciphering the Action of Perfluorohexyloctane Eye Drops to Reduce Ocular Discomfort and Pain.
• Sheppard JD, et al. A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study.
• Tauber J, et al. NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study.
• Akpek EK, et al. Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial.